Abstract
The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy with evidence that their use led to improved lung function and quality of life. However, the use of LABAs has raised safety concerns, such as their potential to provoke severe asthma exacerbations (SAEs) and death. This systematic review of major findings discusses the safety controversy surrounding LABA therapy and provides background for the U.S. Food and Drug Administrations warnings concerning LABA use. Findings from large clinical trials and several meta-analyses are described and compared in terms of their implications for the safety of LABAs. Monotherapy LABA therapy in the treatment of asthma remains controversial and is not recommended by the most recent asthma management guidelines. Despite the existence of numerous published studies, we conclude that more well-designed research on this topic --- to determine whether LABAs are associated with SAEs, such as asthma-related hospitalizations, intubations, and emergency room visits, or death --- is required. Particularly needed is research that makes use of large, secondary longitudinal databases.
Keywords: Long-acting beta agonists (LABAs), asthma, SMART trial, safety controversy, African Americans, pediatric LABA use
Current Drug Safety
Title: Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma
Volume: 5 Issue: 3
Author(s): Boyang Bian, Christina M.L. Kelton, Patricia R. Wigle and Jeff J. Guo
Affiliation:
Keywords: Long-acting beta agonists (LABAs), asthma, SMART trial, safety controversy, African Americans, pediatric LABA use
Abstract: The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy with evidence that their use led to improved lung function and quality of life. However, the use of LABAs has raised safety concerns, such as their potential to provoke severe asthma exacerbations (SAEs) and death. This systematic review of major findings discusses the safety controversy surrounding LABA therapy and provides background for the U.S. Food and Drug Administrations warnings concerning LABA use. Findings from large clinical trials and several meta-analyses are described and compared in terms of their implications for the safety of LABAs. Monotherapy LABA therapy in the treatment of asthma remains controversial and is not recommended by the most recent asthma management guidelines. Despite the existence of numerous published studies, we conclude that more well-designed research on this topic --- to determine whether LABAs are associated with SAEs, such as asthma-related hospitalizations, intubations, and emergency room visits, or death --- is required. Particularly needed is research that makes use of large, secondary longitudinal databases.
Export Options
About this article
Cite this article as:
Bian Boyang, M.L. Kelton Christina, R. Wigle Patricia and J. Guo Jeff, Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma, Current Drug Safety 2010; 5 (3) . https://dx.doi.org/10.2174/157488610791698316
DOI https://dx.doi.org/10.2174/157488610791698316 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Amidine-Based Bioactive Compounds for the Regulation of Arginine Metabolism
Mini-Reviews in Medicinal Chemistry The Safety of Bisphosphonate Use in Premenopausal Women on Corticosteroids
Current Drug Safety Virus, Oncolytic Virus and Human Prostate Cancer
Current Cancer Drug Targets The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews Antimicrobial Peptides in Burns and Wounds
Current Protein & Peptide Science IL-23/Th17 Axis: A Potential Therapeutic Target of Psoriasis
Current Drug Research Reviews Symptoms and Signs
Current Respiratory Medicine Reviews Modified Polysaccharides as Versatile Materials in Controlled Delivery of Antidegenerative Agents
Current Pharmaceutical Design Therapeutic Potential of Antileukotriene Drug-<i>Camellia sinensis</i> Extract Co-Formulation on Histamine Induced Asthma in Guinea Pigs
Current Drug Research Reviews Applications of Circadian Metabolomics
Current Metabolomics 21-Hydroxy-6,19-epoxyprogesterone: A Promising Therapeutic Agent and a Molecular Tool for Deciphering Glucocorticoid Action
Mini-Reviews in Medicinal Chemistry Personalised Genetic Intervention for Duchenne Muscular Dystrophy: Antisense Oligomers and Exon Skipping
Current Molecular Pharmacology Hypersensitivity Reactions to Ophthalmic Products
Current Pharmaceutical Design Type 2 Innate Lymphoid Cells in Allergic Disease
Current Immunology Reviews (Discontinued) Lipid-Activated Nuclear Receptors and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhalational Anesthetics in Acute Severe Asthma
Current Drug Targets The Potential of Desirability Function Strategy in Chemometric Optimization of ICP-AES for Platinum Group Elements and Gold
Current Analytical Chemistry Review of Vital Signs Monitoring Systems – Patient’s Acceptability, Issues and Challenges
Neuroscience and Biomedical Engineering (Discontinued) Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs
Current Topics in Medicinal Chemistry Argemone mexicana: A Boon to Medicinal and Pharmacological Approaches in Current Scenario
Cardiovascular & Hematological Agents in Medicinal Chemistry